17:56 , Feb 15, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Candida Mouse studies suggest inhibiting JNK1 could help treat Candida albicans infection. In a mouse model of C. albicans infection, knockout of JNK1 or two JNK1 inhibitor tool compounds decreased fungal burden and inflammation...
17:40 , Nov 15, 2016 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Encephalitis Cell culture and mouse studies suggest inhibiting JNK1 or its substrate AP-1 could help treat the viral infection Japanese encephalitis (JE). In JE virus-infected human glioma and murine microglial cell lines, a JNK...
07:00 , Aug 18, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: c-jun N-terminal kinase (JNK); JNK1 (MAPK8)

Dermatology INDICATION: Dermatitis Mouse studies suggest that inhibiting JNK could help treat atopic dermatitis. In a mouse model of atopic dermatitis, epidermal levels of JNK were higher than in normal mice. In cultured keratinocytes from...
08:00 , Feb 19, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: c-jun N-terminal kinase 2 (JNK2; MAPK9); JNK3 (MAPK10)

Neurology INDICATION: Neurology In vitro studies have identified aminopyrazole-based JNK2 /3-selective inhibitors that could help treat neurodegenerative diseases linked to neuronal oxidative stress. In vitro, the lead compound inhibited JNK2, JNK3 and JNK1 at IC50...
07:00 , Aug 18, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Diabetes; liver failure c-Jun N-terminal kinase (JNK) In vitro and mouse studies suggest compounds blocking both the ATP- and substrate-binding sites...
07:00 , Apr 28, 2011 |  BC Innovations  |  Targets & Mechanisms

MAPping out aneurysm

A team from The Johns Hopkins University School of Medicine has uncovered a role for the MAP kinase pathway in aortic aneurysms caused by the genetic disorder Marfan syndrome. The findings could open up a...
07:00 , Apr 28, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Marfan syndrome MAP kinase 3 (MAPK3; ERK-1); MAPK1 (ERK-2); MAP kinase kinase 1 (MAP2K1; MEK1); MAP2K2 (MEK2); c-jun N-terminal kinase...
08:00 , Jan 6, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Rheumatoid arthritis (RA) c-Jun N-terminal kinase 1 (JNK1; MAPK8) Studies in mice suggest that inhibiting JNK1 could help treat RA. In a mouse model...
07:00 , Aug 16, 2010 |  BC Week In Review  |  Company News

PregLem, Merck KGaA deal

Merck's Merck Serono S.A. unit granted PregLem exclusive, worldwide rights to develop and commercialize bentamapimod . Merck will receive an upfront payment and is eligible for milestones and royalties. PregLem said it plans to begin...
08:00 , Dec 17, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology c-Jun N-terminal kinase (JNK) Studies in cell culture and in rodents identified biaryl-substituted aminopyrimidine JNK inhibitors that could help treat neurodegenerative diseases. Biochemical and...